Skip to main content
Clinical Trials/ISRCTN12590498
ISRCTN12590498
Completed
未知

A randomised, double-blind, placebo-controlled study on the impact of Lorazepam on approach/avoidance behaviour in healthy individuals

Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)0 sites60 target enrollmentDecember 8, 2014

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)
Enrollment
60
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

  1. 2017 results in https://www.ncbi.nlm.nih.gov/pubmed/28364943 (added 23/01/2019)
Registry
who.int
Start Date
December 8, 2014
End Date
August 1, 2015
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)

Eligibility Criteria

Inclusion Criteria

  • 1\. Informed Consent as documented by signature
  • 2\. Age 18 – 40 years

Exclusion Criteria

  • 1\. Contraindications to benzodiazepines: dependence or former dependence, history of allergic reactions, history of hypotonia associated with benzodiazepines
  • 2\. Use of any drugs in the 2 weeks prior to the study with the exception of contraceptive drugs and incidental use of NSARs or paracetamol
  • 3\. Women who are pregnant or breast feeding
  • 4\. Intention to become pregnant during the course of the study
  • 5\. Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases
  • 6\. Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)
  • 7\. Any history of psychiatric, neurological, dependence or systemic/rheumatic disease
  • 8\. Known or suspected non\-compliance, drug or alcohol abuse
  • 9\. Inability to follow the procedures of the study, e.g. due to language problems
  • 10\. Participation in another study with investigational drug within the 30 days preceding and during the present study

Outcomes

Primary Outcomes

Not specified

Similar Trials